Metformin Research Monograph: Mechanisms and Applications

Clinical Significance

Metformin stands as the cornerstone of type 2 diabetes management, prescribed to over 200 million patients worldwide and recommended as first-line therapy by major clinical guidelines [1]. The landmark Diabetes Prevention Program demonstrated metformin's efficacy in reducing type 2 diabetes incidence by 31% in high-risk individuals, establishing its role in diabetes prevention [2]. The UKPDS 34 trial showed significant reductions in diabetes-related complications in overweight patients, with 39% reduction in myocardial infarction risk [3].

Mechanism of Action

Metformin's therapeutic effects stem from multi-target interactions primarily involving AMPK activation and mitochondrial complex I inhibition [4]. The drug enters cells via organic cation transporters (OCT1, OCT2) and accumulates in hepatocytes, where it inhibits mitochondrial respiratory chain complex I [5]. This inhibition increases the AMP:ATP ratio, subsequently activating AMPK through phosphorylation [6]. Recent research identified the lysosomal AMPK pathway as a key target, with metformin acting through PEN2 at clinically relevant low doses [7].

Activated AMPK triggers multiple downstream effects:

• Suppression of hepatic gluconeogenesis via inhibition of PEPCK and G6Pase
• Enhanced peripheral glucose uptake through GLUT4 translocation
• Improved insulin sensitivity via reduced hepatic glucose output
• Fatty acid oxidation promotion through ACC inhibition [8]

Transport and Pharmacokinetics

Cryo-EM structural studies have revealed metformin's binding conformations with human OCT1 transporter, showing inward occluded, outward open, and outward occluded states [9]. The drug exhibits pH-dependent absorption and is eliminated unchanged via MATE1 and MATE2-K transporters in the kidney [10]. Genetic polymorphisms in these transporters significantly affect metformin pharmacokinetics and therapeutic response.

Pleiotropic Effects and Anti-Aging

Beyond glycemic control, metformin demonstrates remarkable anti-aging properties. A rigorous 40-month study in cynomolgus monkeys showed metformin decelerated aging clocks and provided geroprotective effects [11]. The drug influences telomere dynamics through enhanced RAP1 expression, with gender-specific effects in type 2 diabetes patients [12].

Cancer and Immunotherapy Applications

Emerging evidence supports metformin's anticancer potential. Genome-wide CRISPR screening revealed PKA-driven resistance mechanisms that can be overcome by NSAID combinations for oral cancer prevention [13]. Metformin enhances cancer immunotherapy through SLC5A11-mediated PD-L1 suppression via the AMPK-IRF1 signaling pathway [14].